Zydus gets approval for Phase III trial of sickle cell disease drug | Ahmedabad News
Ahmedabad: Pharma major Zydus Lifesciences on Thursday received approval to conduct a Phase III clinical trial of Desidustat in patients with sickle cell disease, the company said in a stock exchange filing.The 203-day trial, to be conducted in collaboration with the Indian Council of Medical Research (ICMR), will enrol 164 patients. It will assess the…